Does combining antiretroviral agents in a single dosage form enhance quality of life of HIV/AIDS patients? A cost-utility study

Research in Social and Administrative Pharmacy

Volumn 8, Issue 2, 2012, Pages 157-165

  Ganguli, Arijit ^a   Wang, Junling ^a   Gourley, Dick R ^b  

^a UNIVERSITY OF TENNESSEE COLLEGE OF PHARMACY   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

AIDS; Antiretroviral drugs; Combination therapy; Cost utility; HIV; Quality of life; Single pill regimen; Utilities

Indexed keywords

ANTIRETROVIRUS AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; COST BENEFIT ANALYSIS; DRUG COMBINATION; DRUG COST; ECONOMICS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIDDLE AGED; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE;

ADOLESCENT; ADULT; AGED; ANTI-RETROVIRAL AGENTS; COST-BENEFIT ANALYSIS; DRUG COMBINATIONS; DRUG COSTS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; YOUNG ADULT;

EID: 84858289260     PISSN: 15517411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sapharm.2010.12.004     Document Type: Article

References (38)

1. Schackman B.R., Gebo K.A., Walensky R.P., et al. The lifetime cost of current human immunodeficiency virus care in the US. Med Care 2006, 44:990-997.
2. Center for Disease Control and Prevention Epidemiology of HIV/AIDS-US, 1981-2005. MMWR Morb Mortal Wkly Rep 2006, 55:589-592.
3. Piacenti F.J. An update and review of antiretroviral therapy. Pharmacotherapy 2006, 26:1111-1133.
4. Conway B. The role of adherence to antiretroviral therapy in the management of HIV infection. J Acquir Immune Defic Syndr 2007, 45(suppl 1):S14-S18.
5. Moore D.M., Hogg R.S., Yip B., et al. Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. J Acquir Immune Defic Syndr 2005, 40:288-293.
6. Wood E., Hogg R.S., Yip B., Harrigan P.R., O'Shaughnessy M.V., Montaner J.S. The impact of adherence on CD4 cell count responses among HIV-infected patients. J Acquir Immune Defic Syndr 2004, 35:261-268.
7. Wood E., Hogg R.S., Yip B., Harrigan P.R., O'Shaughnessy M.V., Montaner J.S. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 × 10(9) cells/L. Ann Intern Med 2003, 139:810-816.
8. Rosenbach K.A., Allison R., Nadler J.P. Daily dosing of highly active antiretroviral therapy. Clin Infect Dis 2002, 34:686-692.
9. Hawkins T. Impact of once- and twice-daily dosing regimens on adherence and overall safety. AIDS Read 2004, 14:320-331. 334.
10. Portsmouth S.D., Osorio J., McCormick K., et al. Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules. HIV Med 2005, 6:185-190.
11. Dejesus E., Young B., Morales-Ramirez J.O., et al. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. J Acquir Immune Defic Syndr 2009, 51:163-174.
12. Hodder S.L., Mounzer K., Dejesus E., et al. Patient-reported outcomes in virologically suppressed, HIV-1-infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF. AIDS Patient Care STDS 2010, 24:87-96.
13. DeJesus E., Ruane P., McDonald C., et al. Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine. HIV Clin Trials 2008, 9:103-114.
14. Airoldi M., Zaccarelli M., Bisi L., et al. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence 2010, 4:115-125.
15. Brazier J.E., Roberts J. The estimation of a preference-based measure of health from the SF-12. Med Care 2004, 42:851-859.
16. Garratt A.M., Ruta D.A., Abdalla M.I., et al. The SF-36 health survey questionnaire: an outcome measure suitable for routine use within the NHS. BMJ 1993, 306:1440-1444.
17. Brazier J., Roberts J., Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002, 21:271-292.
18. Conner-Spady B., Suarez-Almazor M.E. Variation in the estimation of quality-adjusted life-years by different preference-based instruments. Med Care 2003, 41:791-801.
19. MEPS Medical Expenditure Panel Survey Consolidated Data File, HC-105 Available at:, Accessed 20.12.08. http://www.meps.ahrq.gov/mepsweb/data_stats/download_data/pufs/h105/h105doc.pdf.
20. US FDA Drugs used in the treatment of HIV infection Available at:, Accessed 18.11.08. http://www.fda.gov/ForConsumers/byAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm118915.htm.
21. HAART Chart Approved antiretroviral drugs Available at:, Accessed 05.11.08. http://www.thebody.com/content/treat/art46438.html.
22. McCrone P., Patel A., Knapp M., et al. A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia. J Ment Health Policy Econ 2009, 12:27-31.
23. Austin P.C. Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations. Biom J 2009, 51:171-184.
24. Shah B.R., Laupacis A., Hux J.E., et al. Propensity score methods gave similar results to traditional regression modeling in observational studies: a systematic review. J Clin Epidemiol 2005, 58:550-559.
25. Fenwick E., Claxton K., Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001, 10:779-787.
26. William W.Y. An approximation of skewed healthcare expenditure distribution using mixed model. American Statistical Association Section on Survey Research Methods 2005, 3919-3924.
27. Grosse S.D. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res 2008, 8:165-178.
28. Revicki D.A., Swartz C., Wu A.W., et al. Quality of life outcomes of saquinavir, zalcitabine and combination saquinavir plus zalcitabine therapy for adults with advanced HIV infection with CD4 counts between 50 and 300 cells/mm3. Antivir Ther 1999, 4:35-44.
29. Revicki D.A., Moyle G., Stellbrink H.J., et al. Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. PISCES (SV14604) Study Group. AIDS 1999, 13:851-858.
30. Cunningham W.E., Crystal S., Bozzette S., et al. The association of health-related quality of life with survival among persons with HIV infection in the US. J Gen Intern Med 2005, 20:21-27.
31. Chan K.S., Revicki D.A. Changes in surrogate laboratory markers, clinical endpoints, and health-related quality of life in patients infected with the human immunodeficiency virus. Eval Health Prof 1998, 21:265-281.
32. Brechtl J.R., Breitbart W., Galietta M., et al. The use of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection: impact on medical, palliative care, and quality of life outcomes. J Pain Symptom Manage 2001, 21:41-51.
33. Starace F., Ammassari A., Trotta M.P., et al. Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002, 31(suppl 3):S136-S139.
34. Hoffman J.M., Shah N.D., Vermeulen L.C., et al. Projecting future drug expenditures-2008. Am J Health Syst Pharm 2008, 65:234-253.
35. Ganguli A., Hong S.H. Impact of new antihypertensive drugs on the healthcare utilization of hypertensive patients. Am J Pharm Benefits 2009, 1:138-144.
36. Zhang Y., Soumerai S.B. Do newer prescription drugs pay for themselves? A reassessment of the evidence. Health Aff (Millwood) 2007, 26:880-886.
37. Miller G.E., Moeller J.F., Stafford R.S. New cardiovascular drugs: patterns of use and association with non-drug health expenditures. Inquiry 2005, 42:397-412.
38. Kaiser Family Foundation HIV/AIDS policy fact sheet Available at:, Accessed 18.11.08. http://www.kff.org/hivaids/upload/7582_03.pdf.